Effects of sodium-nitroprusside and urapidil on gas exchange and ventilation-perfusion relationships in patients with congestive heart failure

Eur Respir J. 1991 Jan;4(1):69-75.

Abstract

Vasodilators usually decrease arterial PO2 in patients with congestive heart failure (CHF) because of alteration in ventilation-perfusion (Va/Q) relationships. The effects of sodium nitroprusside (SNP) and urapidil (U), a new selective alpha 1-receptor antagonist, were investigated in seven patients with CHF. The distribution of ventilation and perfusion was examined using the multiple gas elimination technique. The haemodynamic responses to SNP and U were similar, cardiac index increasing by 25% with SNP and by 31% with U. Despite a similar increase of mixed venous oxygen tension, the arterial PO2 decreased from 11.3 +/- 0.8 to 9.6 +/- 0.6 kPa (p less than 0.01) with SNP but remained unchanged (11.0 +/- 0.9 vs 11.4 +/- 0.8 kPa, NS) with U. SNP and U both increased perfusion to lung units with Va/Q ratios of 0.1 or less with no change in shunt fraction. The fractional perfusion to total low Va/Q ratios (low Va/Q + shunt) was higher with SNP than with U (14.1 +/- 2.6 vs 9.5 +/- 2.3%, p less than 0.01). The results suggest that gas exchange and Va/Q relationships are altered less with U than with SNP in patients with CHF.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Adrenergic alpha-Antagonists / therapeutic use*
  • Female
  • Heart Failure / drug therapy*
  • Hemodynamics / drug effects
  • Humans
  • Male
  • Middle Aged
  • Nitroprusside / therapeutic use*
  • Piperazines / therapeutic use*
  • Pulmonary Circulation / drug effects
  • Pulmonary Gas Exchange / drug effects
  • Ventilation-Perfusion Ratio / drug effects

Substances

  • Adrenergic alpha-Antagonists
  • Piperazines
  • Nitroprusside
  • urapidil